You are here

P&T News

April 20

New technology brings specialists to the bedside
FDA considers therapy for von Willebrand disease

April 17

Cancer specialists examine future payment models to improve care and lower costs
Sandoz makes a move on Teva’s immune modifier
Median progression-free survival is 13.5 months for AZD9291
Pivotal phase III data to be presented at neurology meeting
Nurse-led innovations save more than $28 million annually nationwide, association says

April 16

But some Medicare doctors still face temporary pay cuts
Centers judged on patients' satisfaction
Treatment indicated to reduce risk of hospitalization
Risk is dose-dependent for simvastatin and atorvastatin
Specialty societies give ‘thumbs down’ to low-benefit, high-cost preoperative testing

April 15

Last-minute vote avoids 21% pay cut for Medicare doctors
Method is ‘better than mammography,’ researcher says
Breast cancer drug improves progression-free survival

Pages